Wagner F. Gattaz

gattaz

Currrículo Lattes

Birth: February 10, 1951 in Sao Paulo, Brazil

Citizenship: german, brazilian
Language Fluency: english, german, spanish, portuguese
Address:
Department of Psychiatry
Faculty of Medicine - University of São Paulo
P.O. Box 8091
05403-010 São Paulo - SP - Brazil
Telephone +5511 3069.8010
Telefax: +5511 3062.9029
e-mail: gattaz@usp.br

Education:
Faculty of Medicine, Fundação ABC, Sao Paulo, M.D. (1970-1975)
Neuropsychiatric Clinic, University of Sao Paulo, Resident Neuropsychiatry. (1976-1977)
University of Heidelberg, Doctorate. (1979)
University of Heidelberg, Habilitation (qualification for a full professorship). (1983)
Title of Psychiatrist by the German Medical Council. (1986)
German Medical Approbation. (1989)
Course on Behaviour Therapy. (1988-1990)
Formation in Psychotherapy. (1991-1995)
Title of Psychotherapist by the German Medical Council. (1996)

Professional Experience:
Professor and Chairman of the Department of Psychiatry, Faculty of Medicine,University of São Paulo Since June 1996
Head of the Neurobiology Research Unit at the Central Institute of Mental Health Mannheim (CIMH) 1991-1996
Professor of Psychiatry, University of Heidelberg 1988-1996
Chief Psychiatrist, research ward (CIMH) 1985-1996
Chief Psychiatrist, gerontopsychiatric ward (CIMH) 1988-1996
Deputy Director of the CIMH 1991
Senior Chief Psychiatrist (CIMH) 1990
Chief Psychiatrist, acute ward and day-hospital (CIMH) 1985-1987
Professor of Psychiatry, Department of Psychiatry and
Medical Psychology, Faculty of Medicine, Foundation ABC, Sao Paulo 1983-1984
Visiting Professor at the CIMH 1980-1983
Visiting scientist at the Psychiatric Clinic of the CIMH 1978-1979

Current Research Projects:
Preclinical (Animal Experiments)
Development of animal models for Alzheimer’s disease
Stereotactic manipulation of brain phospholipid metabolism

Clinical Trials
Planning, execution and coordination of unicentric and multicentric clinical trials under
GCP/FDA standards in schizophrenia, major depression, mania and Alzheimer’s disease.
Neurobiology(Schizophrenia, Major Depression, and Alzheimer’s disease)
Brain mapping and psychophysiology (high resolution EEG)
Brain imaging and function (NMR, DTI and NMR-Spectroscopy)
Cell membrane phospholipid turnover in brain (post mortem) and in blood cells
Molecular genetics
Psychiatric epidemiologypidemiology

Editorial Activity:
Assistant Editor, European Archives of Psychiatry and Clinical Neuroscience (1986-1998)
Co-Editor, European Archives of Psychiatry and Clinical Neuroscience (1999-Present)
Editorial Board, European Journal of Psychiatry (1987-Present)
Advisory Editor, Psychopharmacology (1992-Present)
Editorial Board, Biological Psychiatry (1993-1998)
Editorial Board, Psiquiatria Biologica (1993-Present)
Editorial Board, Schizophrenia Research (1994-Present)
Editorial Board, Jornal Brasileiro de Psiquiatria (1995-Present)
Editorial Board, Revista da Asociacion Argentina de Psiquiatras (1996-Present)
Editorial Board, Revista do Hospital da Clínicas da FMUSP (1998-Present)
Editorial Board, The World Journal of Biological Psychiatry (1998-Present)
Editorial Board, Revista Brasileira de Psiquiatria (1998-Present)
Editorial Board, Revista Psiquiatria na Pratica Medica (Portugal) (1998-Present)
Editor, Revista de Psiquiatria Clínica (1998-Present)
Co-editor, Journal of Neural Transmission (1999-Present)
Co-Editor, The World Journal of Biological psychiatry (2000-Present)

Nominations and Membership:
Secretary of the German Society of Biological Psychiatry (1995-1996)
Member, German Society of Biological Psychiatry
Member of the AGNP (Arbeitsgemeinschaft für Neuropsychopharmakologie)
Academia Medicinae & Psychiatriae (USA)
Society of Biological Psychiatry (USA)
Honorary Member, Brazilian Society of Biological Psychiatry
Honorary Member, Asociacion Argentina de Psiquiatras
Member, Scientific Committee, World Federation of the Societies of Biological Psychiatry
Brasilian Academy of Sciences

Recent publications:

2011

  1. Vocational rehabilitation improves cognition and negative symptoms in schizophrenia.
    [ PubMed | Download ]
  2. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer’s disease.
    [ PubMed | Download ]

2010

  1. Diagnosis and biomarkers of predementia in Alzheimer’s disease.
    [ PubMed | Download ]
  2. Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers
    [ PubMed | Download ]
  3. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer’s disease.
    [ PubMed ]
  4. Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease.
    [ PubMed | Download ]
  5. Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia.
    [ PubMed | Download ]
  6. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment.
    [ PubMed | Download ]
  7. Exploring the knowledge contained in neuroimages: statistical discriminant analysis and automatic segmentation of the most significant changes.
    [ PubMed | Download ]
  8. Clinical and biological predictors of Alzheimer’s disease in patients with amnestic mild cognitive impairment
    [ PubMed | Download ]
  9. Apolipoprotein E genotype and cognition in bipolar disorder.
    [ PubMed | Download ]
  10. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression.
    [ PubMed | Download ]
  11. Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement.
    [ PubMed | Download ]
  12. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.
    [ PubMed | Download ]
  13. Proteome analysis of schizophrenia brain tissue.
    [ PubMed | Download ]
  14. Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression.
    [ PubMed | Download ]
  15. Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients.
    [ PubMed ]
  16. Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons.
    [ PubMed | Download ]

2009

  1. Increased serum IL-1beta level in Alzheimer’s disease and mild cognitive impairment.
    [ PubMed | Download ]
  2. Diagnostic transitions in mild cognitive impairment subtypes.
    [ PubMed | Download ]
  3. Omega-3 consumption and sudden cardiac death in schizophrenia.
    [ PubMed | Download ]
  4. EEG alpha peak frequency analysis during memorizing of figures in patients with mild cognitive impairment.
    [ PubMed | Download ]
  5. Recognition of depressive symptoms by physicians.
    [ PubMed | Download ]
  6. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia.
    [ PubMed | Download ]

Anteriores a 2009

  1. Association between BanI genotype and increased phospholipase A2 activity in schizophrenia.
    [ PubMed | Download ]
  2. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. [ PubMed | Download ]
  3. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. [ PubMed | Download ]
  4. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. [ PubMed | Download ]
  5. Centella asiática water extract inhibits iPLA2 and cPLA2 activities in rat cerebellum. [ PubMed | Download ]
  6. Cognitive training increases platelet PLA2 activity in healthy elderly subjects. [ PubMed | Download ]
  7. Cold weather and risk of sudden cardiac death in schizophrenia: finding a new Achilles’ heel? [ PubMed | Download ]
  8. Proteome analysis of human dorsolateral prefrontal cortex using shotgun mass spectrometry. [ PubMed | Download ]
  9. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Phamacopsychiatry: consensus statement. [ PubMed | Download ]
  10. Mild cognitive impairment: cognitive screening or neuropsychological assessment. [ PubMed | Download ]
  11. Language impairment in euthymic, elderly patients with bipolar disorder but no dementia. [ PubMed | Download ]
  12. Conditioning training and retrieval increase phospholipase A2 activity in the cerebral cortex of rats. [ PubMed | Download ]
  13. DNA polymorphisms as tools for spinal cord injury research. [ PubMed ]
  14. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial. [ PubMed | Download ]
  15. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. [ PubMed | Download ]
  16. Phospholipase A(2) activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. [ PubMed | Download ]
  17. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. [ PubMed | Download ]
  18. The neuroprotective effect of dental pulp cells in models of Alzheimer’s and Parkinson’s disease. [ PubMed | Download ]
  19. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. [ PubMed | Download ]
  20. Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: preliminary evidence. [ PubMed ]
  21. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. [ PubMed | Download ]
  22. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease. [ PubMed | Download ]
  23. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. [ PubMed | Download ]
  24. Proteome analysis of schizophrenia patients Wernicke’s area reveals an energy metabolism dysregulation. [ PubMed | Download ]